Secondaries announced 4.10.2015

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Foamix Pharmaceuticals Ltd.
Symbol: FOMX
Price: Last trade $9.42
Trade Date: 4/15
Shares: 5.3 million
Underwriter(s) Barclays, Cowen & Co., Guggenheim Securities
Co Manager(s) Oppenheimer & Co.
Rating=Subscription Needed